For more information on these studies, contact Cancer Research at (601) 984-1095.
S1801- A Phase II Randomized Study of Adjuvant Versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma
The purpose of this study is to see if treating melanoma with the study drug pembrolizumab, before versus after surgery will affect the disease.
We are doing this study because we want to find out which approach is better for treating high-risk melanoma.
There are several treatment options for high-risk melanoma. Patients whose melanoma is surgically removable will normally have surgery before getting treatment. Though surgery followed by pembrolizumab has been selected as the “standard” treatment option for this study, other approaches are often used. FDA-approved treatments after surgery include interferon, ipilimumab, and nivolumab.